Established in 1978, Biocon is India's premier biotechnology company. Headquartered in Bangalore, Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare.

Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specialising in biopharmaceuticals, custom research, clinical research and enzymes. Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high-value solutions at any stage in the life cycle of a drug—from discovery to market. Biocon's vision is to be an integrated biopharmaceutical enterprise of global distinction.

The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon's products in the biopharmaceutical category includes: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, digestive-aid enzymes, haemostatic agents, hepatoprotective agents, immunosuppressants, nutraceuticals and orthopaedic agents. Products in the enzymes category include: amylases, cellulases, esterases, hemicellulases/ xylanases, oxidases, pectinases, proteases, tannase.

With its strong focus on R&D, Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in the early stage of drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials.

Biocon's success has been characterised by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India's first and leading biotechnology company, Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has recently launched Arogya Raksha Yojana, a unique health initiative for rural India.

Biocon aims to continuously create growth in different areas of the company, to manufacture human insulin INSUGEN^TM globally, using a Pichia expression system. In addition, Biocon is India's largest producer of human insulin and is positioned to be India’s first company to set up commercial production of monoclonal antibodies.